Gemini Therapeutics Inc.'s $42.5 million series A round will "take us into the clinic with multiple programs," CEO James McLaughlin told BioWorld. The Cambridge, Mass.-based firm is working on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, with "about 18 months of R&D under our belt," he said.